GCT-103 is under clinical development by S-Quatre and currently in Phase II for Cerebral Palsy. According to GlobalData, Phase II drugs for Cerebral Palsy does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the GCT-103 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GCT-103 overview
GCT-103 is under development for the treatment of cerebral palsy. It is administered through intravenous route. The drug candidate comprises of stem cells derived from human exfoliated deciduous teeth (SHED).
S-Quatre overview
S-Quatre, a subsidiary of Kidswell Bio Corp, is a biotechnology company that is engaged in developing cell therapeutics for various intractable diseases. The company is headquartered in Chuo-ku, Tokyo, Japan.
For a complete picture of GCT-103’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
